Merck KGaA

  • WKN: 659990
  • ISIN: DE0006599905
  • Land: Deutschland

Nachricht vom 20.01.2021 | 13:30

Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)

Merck KGaA / Key word(s): Study/Study results
Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)

20-Jan-2021 / 13:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.

While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1 (the "Clinical Trial"), the Independent Data Monitoring Committee recommended on January 19, 2021 to discontinue the Clinical Trial. Based on this recommendation, the Company has made the decision to discontinue the Clinical Trial, as the
study is unlikely to meet the primary efficacy endpoint. The recommendation by the Independent Data Monitoring Committee and the Company's decision is related only to this Clinical Trial.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

An investor and analyst call with the Company's management is scheduled for 2:00 pm (CET).



Andreas Cezanne - Head of Corporate Media Relations
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151-14542702

20-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

International School Augsburg (ISA) – erste Schule in Deutschland geht an die Börse

Die International School Augsburg – ISA- gemeinnützige AG geht als erste Schule in Deutschland an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Mit dem geplanten Emissionserlös soll ein Campus-Neubau finanziert werden, um die hohe Nachfrage bedienen zu können. In unserer Researchstudie haben wir die hohe Bedeutung der ISA für den regionalen Wirtschaftsstandort, eine hohe Stabilität der Geschäftsentwicklung sowie hohe Sicherheiten durch vorhandene Sachwerte ermittelt. Das Rating lautet KAUFEN.

News im Fokus

Linde Recognized as One of the 2021 World's Most Ethical Companies

01. März 2021, 12:00

Aktueller Webcast

HelloFresh SE

Publication of the Annual Report & Earnings Call

02. März 2021

Aktuelle Research-Studie

SBF AG

Original-Research: SBF AG (von Montega AG): Kaufen

01. März 2021